Biogen Inc. presented additional results from the Phase 1b study of salanersen, an investigational novel antisense oligonucleotide (ASO) given once a year for spinal muscular atrophy (SMA), at the ...

Immunic, Inc. (Nasdaq: IMUX), a late-stage biotechnology company pioneering the development of novel oral therapies for neurologic and gastrointestinal diseases, today announced that the European ...

SEDA Experts LLC, a leading expert witness firm providing world-class financial expert witness services, announced today that Matthew L. Sperling joined the firm as Managing Director.New York, NY, ...

Results show that targeting the underlying cause of Dravet syndrome with zorevunersen may improve outcomes for people with this rare, devastating genetic neurodevelopmental disease– –Data support ...